Korro Bio Inc
For the period ended Jun 30, 2024. Filed Aug 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
Item 5. Other Information.
On June 13, 2024, Steve Colletti, ourformer Chief Scientific Officer, adopted a trading plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act for the potential sale of up to 6,257 shares of our common stock issuable upon the exercise of stock options. The trading plan would have expired on December 9, 2024 per its terms had it not been terminated following his departure from our company.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.